NEW YORK — Chinese molecular diagnostics firm AmoyDx said on Monday that it has partnered with Eisai on the development and registration of companion diagnostic tests.
Specific terms of the deal were not disclosed.
"We have been developing highly effective diagnostic solutions to guide treatment decisions of clinical precision oncology based on various technical platforms," AmoyDx Founder and CEO Li-mou Zheng said in a statement. "We are happy to have the opportunity of working together with Eisai on emerging valuable targets."
In June, AmoyDx signed an agreement to work with Premia Holdings to conduct large-scale cancer patient screening in Asia for a targeted cancer drug under development by Loxo Oncology. It also began working with Sanomics earlier this year on a multigene mutation detection kit and received approval for a lung cancer companion diagnostic in South Korea last year.
Tokyo-based Eisai develops drugs primarily for the neurology and oncology markets, including treatments for Parkinson's disease, Alzheimer's disease, breast cancer, and lymphomas.